Survodutide activates glucagon and GLP-1 receptors and has phase III obesity research. Weight outcomes should be read with the comparator, follow-up and adverse events.
What did phase III report?
A 725-participant trial followed adults for 76 weeks. Mean weight reductions were about 12–13% in two survodutide groups versus about 5% with placebo in an analysis accounting for early discontinuation. Gastrointestinal symptoms were common. Reference: Survodutide phase III obesity trial (2026)
Does this predict every person’s result?
No. A group mean is not an individual forecast. Participants also received lifestyle counseling; outcomes in a different context may differ.
How should it be compared with other agents?
Do not rank survodutide, tirzepatide and retatrutide by percentages from separate trials alone. Populations, duration and analysis methods differ. Direct comparative trials are more informative.
Frequently asked questions
Is Survodutide another name for Retatrutide?
No. They are distinct compounds with separate research.
Does phase III mean worldwide approval?
No. Trial phase and country-specific authorization must be checked separately.
How should this article be used?
Use it to identify the substance, understand what the cited research measured, and prepare questions for a qualified clinician. It is educational information, not an individual treatment plan.